A commercial-stage psychedelic drug manufacturer.
Optimi Health Corp. manufactures finished-dose psilocybin and MDMA capsules at a Health Canada Drug Establishment-licensed facility in Princeton, British Columbia, and supplies them to authorized psychiatrists in Australia under the TGA Authorized Prescriber Scheme.
Natural Psilocybin Extract, MDMA 60 mg, MDMA 40 mg. Manufactured under Health Canada Drug Establishment Licence. Supplied to authorized prescribers under TGA Authorized Prescriber Scheme, Australia.
Overview.
Optimi Health Corp. (CSE: OPTI · OTCQX: OPTHF) produces finished-dose psilocybin and MDMA capsules for regulated therapeutic use. The Company operates a Health Canada GMP-compliant facility and holds a Drug Establishment Licence authorizing commercial manufacture, packaging, testing, and international export of controlled drug products.
Active supply operations began under the Australian Authorized Prescriber Scheme in 2024. Product is dispensed to patients through authorized clinics for post-traumatic stress disorder and treatment-resistant depression.
The Company is structured to scale into additional jurisdictions as regulatory access develops, including the United States upon federal rescheduling.